STAAR Surgical — Third Quarter 2026 Earnings Summary

STAAR Surgical reported third-quarter 2026 net sales of $83.4 million, representing a 12% year-over-year decline that included a significant impact from previously deferred China sales recognized in the prior year. The company achieved a net income of $5.6 million, or $0.11 per diluted share, while Adjusted EBITDA reached $14.4 million. For the first nine months of 2026, the company recorded record revenue of $270.5 million and net income of $18.8 million. Key operational developments included the completion of a manufacturing transition for the Chinese market to Switzerland to reduce tariff exposure and the authorization of a $50 million share repurchase program.